Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Denosumab is protective against vertebral fractures among osteoporotic people with diabetes, reports a recent meta-analysis.
Treatment with the PCSK9* inhibitor alirocumab led to clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) among adults with homozygous familial hypercholesterolaemia (HoFH), according to data from the ODYSSEY-HoFH** trial presented at the ACC.20/WCC Virtual meeting.
Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).
Among patients with nonvalvular atrial fibrillation (AF), treatment with apixaban was associated with a lower rate of ischaemic stroke, systemic embolism, and major bleeding compared with rivaroxaban, according to a large study assessing patients in routine care.
In children with type 1 diabetes, small doses of subcutaneous glucagon appear to be safe and effective in preventing hypoglycaemic episodes in cases of nausea, vomit or food refusal, a study has shown.
Treatment with nintedanib slows disease progression of idiopathic pulmonary fibrosis (IPF) in Asian patients, and this beneficial effect persists over the long term, with acceptable safety and tolerability profile, suggest the results from a subgroup analysis of data from INPULSIS-ON, the open-label extension of the INPULSIS trials.
Special Reports
Bumrungrad International Hospital was founded in 1980 and has since grown to become one of the most reputable hospitals in the region. The recipient of numerous international awards and accreditations, Bumrungrad International is one of the largest private hospitals in Southeast Asia, catering to over 1.1 million patients from over 190 countries annually.
In an exclusive interview with MIMS, Kenny Lim, Chief Information Technology Officer of Bumrungrad International Hospital shared his views on how the hospital has continued to improve its services to patients with particular emphasis on the use of clinical decisions support tools.
In an exclusive interview with MIMS, Kenny Lim, Chief Information Technology Officer of Bumrungrad International Hospital shared his views on how the hospital has continued to improve its services to patients with particular emphasis on the use of clinical decisions support tools.
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab
Fenofibrate 145 mg, simvastatin 20 mg FC tab
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Conference Reports
A substudy of the REDUCE-IT* trial – REDUCE-IT EPA** – presented at the ACC.20/WCC Virtual meeting shows that the level of eicosapentaenoic acid (EPA) in the blood achieved from the consumption of icosapent ethyl (IE) – a pure, stable EPA ethyl ester – propelled the substantial reductions in cardiovascular (CV) event rates.
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.
A long-acting (LA) injectable therapeutic regimen comprising the integrase strand-transfer inhibitor cabotegravir and the nonnucleoside reverse-transcriptase inhibitor rilpivirine maintained viral suppression among virologically suppressed adults with HIV-1, according to the week 96 results of the phase III FLAIR* trial.
Adding cilostazol to other antiplatelet agents could potentially reduce in-stent restenosis (ISR) among patients with carotid artery stenosis who undergo carotid artery stenting (CAS), according to results of the CAS-CARE* trial presented at ISC 2020.
Apixaban
outperformed warfarin in preventing ischaemic events regardless of prior stroke,
transient ischaemic attack (TIA), or thromboembolic event (TE) in patients with
atrial fibrillation (AF) with recent acute coronary syndrome (ACS) or percutaneous
coronary intervention (PCI), a
prespecified secondary analysis of the AUGUSTUS trial has shown.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Multimedia
